pubmed-article:17534686 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0796392 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0021735 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
pubmed-article:17534686 | lifeskim:mentions | umls-concept:C0332173 | lld:lifeskim |
pubmed-article:17534686 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:17534686 | pubmed:dateCreated | 2007-7-27 | lld:pubmed |
pubmed-article:17534686 | pubmed:abstractText | Vascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-alpha2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic melanoma. | lld:pubmed |
pubmed-article:17534686 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:language | eng | lld:pubmed |
pubmed-article:17534686 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17534686 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17534686 | pubmed:month | Aug | lld:pubmed |
pubmed-article:17534686 | pubmed:issn | 1068-9265 | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:WalkerMichael... | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:YoungDonnD | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:VarkerKimberl... | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:ChenHelen XHX | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:CarsonWilliam... | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:LesinskiGrego... | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:JensenRhondaR | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:KendraKariK | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:LehmanAmyA | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:KefauverChery... | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:WuHaifengH | lld:pubmed |
pubmed-article:17534686 | pubmed:author | pubmed-author:BiberJennifer... | lld:pubmed |
pubmed-article:17534686 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17534686 | pubmed:volume | 14 | lld:pubmed |
pubmed-article:17534686 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17534686 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17534686 | pubmed:pagination | 2367-76 | lld:pubmed |
pubmed-article:17534686 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:meshHeading | pubmed-meshheading:17534686... | lld:pubmed |
pubmed-article:17534686 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17534686 | pubmed:articleTitle | A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. | lld:pubmed |
pubmed-article:17534686 | pubmed:affiliation | Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, N924 Doan Hall, 410 W 10th Avenue, Columbus, Ohio 43210, USA. | lld:pubmed |
pubmed-article:17534686 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17534686 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:17534686 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:17534686 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
pubmed-article:17534686 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17534686 | lld:pubmed |